N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial
PV Magalhaes, OM Dean, AI Bush, DL Copolov, GS Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk
Journal of Affective Disorders | ELSEVIER SCIENCE BV | Published : 2011
This trial was supported by a grant from the Stanley Medical Research Institute, as well as the Mental Health Research Institute of Victoria.Dr. Magalhaes is supported by a split doctoral scholarship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil.Prof. Malhi has served on a number of international and national pharmaceutical advisory boards, received funding for research and has been in receipt of honoraria for talks at sponsored meetings worldwide involving the following companies: Astra Zeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Organon, Pfizer, Ranbaxy, Servier and Wyeth.Prof. Berk has received research support from: Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier. He has been a speaker for Speaker: Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay, Wyeth. He has been a consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Servier.